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To colonize the liver, colon cancer metastases must overcome hypoxia and other metabolic stress.
Loo et al. now show thatmetastatic cells achieve this by decreasingmiR-483 andmiR-551a expres-
sion, which derepresses creatine kinase expression and allows energy to be captured from extra-
cellular ATP through generation and import of phosphocreatine.It has long been appreciated that cancer
cells exhibit altered patterns of meta-
bolism. The century-old observation of
aerobic glycolysis—or, the Warburg Ef-
fect—has evolved into a more nuanced
and context-specific understanding of
how cancer cells reprogram their meta-
bolism to meet the biosynthetic demands
of rapid proliferation and overcome meta-
bolic stress imposed by themicroenviron-
ment (Hanahan and Weinberg, 2011).
In this issue of Cell, in an elegant series
of experiments, Loo et al. (2015) now
demonstrate that downregulation of spe-
cific microRNAs (miRNAs) allows meta-
static colon cancer cells to adapt meta-
bolically to the harsh conditions in the
liver by using a secreted liver metabolite
to scavenge energy from the extracellular
environment.
Several lines of evidence have sug-
gested key roles for miRNAs in can-
cer progression and metabolism. Broad
dysregulation of miRNA expression ac-
companies tumorigenesis (Volinia et al.,
2006), while loss of specific miRNAs is
associated with promotion of metastasis
both experimentally and clinically (Tava-
zoie et al., 2008). miRNAs also regulate
key enzymes important for maintaining
the cancer metabolic program. For ex-
ample, MYC enhances cancer glutamine
metabolism in part by suppressing miR-
23a/b, leading to upregulation of the
target glutaminase (Gao et al., 2009),
and mTOR activation promotes cancer
glycolysis in part by suppressing miR-
143 and upregulating its target, hexo-
kinase 2 (Fang et al., 2012). Using twoindependent in vivo selection techniques
in mice, Loo et al. demonstrate that
silencing of miR-483 and miR-551a, both
of which target creatine kinase, brain-
type (CKB), promotes metastasis of colon
cancer cells to the liver. But how does
derepression of CKB expression enhance
metastatic colonization?
The liver is considerably hypoxic and
may have uneven levels of glucose in
the interstitial space due to competition
from neighboring hepatocytes. Because
oxygen and glucose are key substrates
for oxidative and glycolytic metabolism,
colon cancer cells that metastasize to
the liver experience metabolic stress.
To overcome this stress, they capitalize
on another metabolic feature of the
liver—synthesis and secretion of crea-
tine by hepatocytes. By suppressing
miR-483 and miR-551a, colon cancer
cells upregulate expression of their
common target, CKB, and secrete it
into the extracellular space, where it
catalyzes formation of phosphocreatine
from creatine and ATP. Phosphocreatine
is then imported back into colon cancer
cells through the transporter SLC6A8,
where it is used to regenerate ATP
needed for cellular functions (Figure 1).
Thus, by downregulating miR-483 and
miR-551a, metastatic colon cancer cells
are able to bypass intracellular glyco-
lytic and oxidative metabolism by acti-
vating an alternative metabolic pathway,
whereby they scavenge energy from the
extracellular environment in the form of
phosphocreatine and shuttle it into the
cell.Cell 160Emerging evidence suggests that there
may be a high degree of organ speci-
ficity in selection for metabolic traits
enabling successful metastatic dissemi-
nation. While Loo et al. define a metabolic
selection mechanism for colon cancer
colonization of the liver, previous work
has shown that fatty acids secreted by
adipocytes in the omentum fuel growth
of ovarian cancer metastases expressing
higher levels of fatty acid-binding protein
4—a metabolic explanation for the predi-
lection of ovarian cancer cells to metasta-
size to the omentum compared to neigh-
boring tissues and organs (Nieman et al.,
2011). Other sites of metastasis may
also have uniquemacrometabolic proper-
ties that enhance metastatic capacity of
cancer cells with complementary meta-
bolic proclivities. For instance, two com-
mon sites of metastasis, the brain and
the lungs (Nguyen et al., 2009), have
high basal levels of glucose and oxy-
gen perfusion, respectively, which may
contribute to the high degree of metasta-
tic colonization of these organs compared
with others.
Notably, loss of miR-483 and miR-551a
and increased expression of CKB, as well
as SLC6A8, are observed in clinical sam-
ples of colon cancer liver metastases
compared to primary colon tumors, sug-
gesting a possible therapeutic opportu-
nity. Indeed, the authors show that viral
rescue of both miR-483 and miR-551a,
as well as pharmacological inhibition
of CKB with cyclocreatine, substantially
decrease the extent of liver metastasis
in a mouse model of metastatic colon, January 29, 2015 ª2015 Elsevier Inc. 363
Figure 1. Phosphocreatine Fuels Metastatic Colonization of the Liver
Reduced miR-483 and miR-551a levels in metastatic colon cancer cells liberates expression of
their mutual target, brain-type creatine kinase (CKB). CKB secreted by the metastatic cells in the liver
phosphorylates extracellular creatine produced by hepatocytes using extracellular ATP to generate
phosphocreatine. Extracellular phosphocreatine is imported into metastatic colon cancer cells by the
transporter SLC6A8. Phosphocreatine is then used to regenerate the ATP needed to sustain the cell. This
alternative metabolic pathway using extracellular phosphocreatine enables metastatic cells to survive
metabolic stress imposed by the liver microenvironment during initial organ colonization, before tumor
vascularization delivers canonical metabolic substrates.cancer. Importantly, the reliance on phos-
phocreatine as an energy source for liver
metastases may not be limited to colon
cancer. Loo et al. show that pancreatic
cancer cells, which also metastasize to
the liver, suffer a similar decrease in met-
astatic capacity when CKB levels are
depleted. Little has been reported on
CKB levels in cancer, but it will be inter-
esting to assess whether CKB levels
correlate with a propensity to metastasize
to the liver in other cancer subtypes.
The findings by Loo et al. suggest that
targeting phosphocreatine metabolism
may reduce liver metastasis in colon can-
cer patients. However, to successfully
translate these findings to the clinic, it
will be important to determine whether
reliance of liver metastases on phospho-
creatine metabolism changes at different
stages of disease. Viral rescue of miR-
483 and miR-551a and pharmacological
inhibition of CKB reducemetastatic tumor
burden when administered within 24 hr of364 Cell 160, January 29, 2015 ª2015 Elsevieinjecting mice with colon cancer cells,
suggesting that targeting phosphocrea-
tine metabolism could be of clinical utility
for patients with early disseminated dis-
ease to prevent development of liver me-
tastases. But for patients with detectable
secondary lesions, the value of targeting
phosphocreatine metabolism remains
unclear. Phosphocreatine metabolism
may be most important for cancer cells
to combat metabolic stress upon initial
seeding of the liver, before expansion
into a secondary tumor, when tumor-
induced vasculature can deliver canonical
metabolic substrates. Bolstering the idea
that initial organ colonization and subse-
quent tumor expansion require different
metabolic programs, circulating breast
cancer cells were recently shown to
exhibit increased oxidative metabolism
compared to the primary tumor and sec-
ondary tumor outgrowths in the lungs
(LeBleu et al., 2014). Additionally, liver
metastases in colorectal cancer patientsr Inc.exhibit glycolytic metabolism, according
to PET studies using the glucose analog
18F-fluorodeoxyglucose (Maffione et al.,
2015).
Together, these data suggest that met-
astatic cells may require a metabolic pro-
gram focused on energy generation to
survive metabolic stress upon initial colo-
nization of a site, and may switch to a
program using canonical metabolic sub-
strates for growth post-vascularization.
Understanding the dynamics of metabolic
transitions between initial cancer dissem-
ination, liver colonization, and metastatic
outgrowth will aid selection of colon
cancer patients who will benefit most
from approaches to target phosphocrea-
tine metabolism.REFERENCES
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